TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01772641

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scheduled Gradual Reduction + Varenicline
Description: Participants will receive a four-week Scheduled Gradual Reduction (SGR) intervention in which participants cut down on the number of cigarettes smoked. This is done through a smoking schedule in which participants smoke a cigarette at given fixed and equal intervals throughout their waking day. Additionally, they will take 0.5 mg of Varenicline (VN) once a day for the first three days, then 0.5 mg twice a day for the next four days, and they will continue for 13 weeks at 1.0 mg twice per day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scheduled Gradual Reduction + Placebo Drug
Description: Participants will receive a four-week Scheduled Gradual Reduction (SGR) intervention in which participants cut down on the number of cigarettes smoked. This is done through a smoking schedule in which participants smoke a cigarette at given fixed and equal intervals throughout their waking day. Additionally, they will take placebo pills matching the schedule of the VN group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Basic Advice + Varenicline
Description: Participants will receive informational pamphlets with advice about quitting smoking. Additionally, they will take 0.5 mg of Varenicline (VN) once a day for the first three days, then 0.5 mg twice a day for the next four days, and they will continue for 13 weeks at 1.0 mg twice per day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Basic Advice + Placebo Drug
Description: Participants will receive informational pamphlets with advice about quitting smoking. Additionally, they will take placebo pills matching the schedule of the VN group.
Study: NCT03149250

Intervention type: DIAGNOSTIC_TEST
Intervention: Aggregometry, Monitoring of plasmatic hemostasis
Description: Multiple Electrode Aggregometry using the Multiplate system Coagulation factor analyses (FXIII, FVIII, vWF) Parameters of conventional coagulation testing (aPTT, INR, Platelet count)

Intervention type: DIAGNOSTIC_TEST
Intervention: Aggregometry, Monitoring of plasmatic hemostasis
Description: Multiple Electrode Aggregometry using the Multiplate system Coagulation factor analyses (FXIII, FVIII, vWF) Parameters of conventional coagulation testing (aPTT, INR, Platelet count)

Intervention type: DIAGNOSTIC_TEST
Intervention: Aggregometry, Monitoring of plasmatic hemostasis
Description: Multiple Electrode Aggregometry using the Multiplate system Coagulation factor analyses (FXIII, FVIII, vWF) Parameters of conventional coagulation testing (aPTT, INR, Platelet count)
Study: NCT03561181

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine
Description: Group 1:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine
Description: Group 2:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 5 µg S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine.
Study: NCT01067404

Intervention type: BIOLOGICAL
Intervention: Trivalent inactivated influenza vaccine
Description: 0.25mL dose of 2009-10 trivalent inactivated influenza vaccine (TIV)
Study: NCT01364428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Injected subcutaneously (under the skin) once daily, in combination with unchanged pre-trial oral anti-diabetic drug (OAD) treatment.~Dose was individually adjusted.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Injected subcutaneously (under the skin) once daily, in combination with unchanged pre-trial oral anti-diabetic drug (OAD) treatment.~Dose was individually adjusted.
Study: NCT01378793

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Acupressure
Description: Apply pressure (stimulate) to the 9 acupoints for 3 minutes per point giving a total treatment time of 27 minutes done once daily for a period of 6 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stimulating Acupressure
Description: Apply pressure (stimulate) to the 10 excitatory acupoints for 3 minutes per point giving a total treatment time of 30 minutes done once daily for a period of 6 weeks.
Study: NCT04237428

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 CAR-T cells infusion
Description: Biological: CD19 CAR-T cells infusion Biological: CD19 CAR-T cells infusion. Pretreatment: patients enrolled in this study will receive cyclophosphamide or fludarabine plus cyclophosphamide. CD19 CAR-T cells infusion are allowed within 2 weeks after treatment.~CD19 CAR-T cells infusion: 30-60 minutes before infusion, H1 anti-histamine agents are applied (acetaminophen 30mg,po.; promethazine 25mg,i.v. ; diphenhydramine 0.5-1mg/kg, no more than 50mg.). Non-physiological doses of corticosteroids are not applied for patients during treatment or recovery unless a life-threatening emergency occurs. CD19 CAR-T cells are infused into patients for one time, the number of infused CD19 CAR-T cells are 0.5-4×10\^6/kg.
Study: NCT00743652

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent Pneumococcal Conjugate Vaccine
Description: 4 doses of 13vPnC (0.5ml, IM) will be administered. (3 doses infant series, and 1 toddler dose)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent Pneumococcal Conjugate Vaccine
Description: 3 doses of 13vPnC (0.5ml, IM) will be administered. (2 doses for infant series catch-up, and 1 toddler dose)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent Pneumococcal Conjugate Vaccine
Description: 2 doses of 13vPnC (0.5ml, IM) will be administered. (1 dose infant series catch-up, and 1 toddler dose)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent Pneumococcal Conjugate Vaccine
Description: 2 doses of 13vPnC (0.5ml, IM) will be administered. (2 catch-up dose(s) greater than 60 days apart )

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent Pneumococcal Conjugate Vaccine
Description: 1 dose of 13vPnC (0.5ml, IM) will be administered. (1 catch-up dose)
Study: NCT01839448

Intervention type: BIOLOGICAL
Intervention: Post-partum oral glucose tolerance test
Description: All patients will have an oral glucose tolerance test at 4 to 12 weeks after the end of pregnancy. Study representatives will contact patients by phone to remind them of the necessity of this test, and its importance for their health.

Intervention type: BIOLOGICAL
Intervention: Post-partum oral glucose tolerance test
Description: All patients will have an oral glucose tolerance test at 4 to 12 weeks after the end of pregnancy. Study representatives will contact patients by phone to remind them of the necessity of this test, and its importance for their health.
Study: NCT00981006

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: human cardiac stem cells
Description: Single intramyocardial Injection of autologous hCSCs : 20 cites of infarcted myocardium Implantation of gelatin hydrogel sheet incorporating bFGF: 200 microgram. CABG surgery.
Study: NCT01632085

Intervention type: DEVICE
Group type: OTHER
Intervention: The two groups SU and R are defined by the device with which intubation is performed after a first laryngoscopy done with the other device.
Description: Group SU (Single Use or Laryngobloc ®): the first laryngoscopy is performed with the R and the second laryngoscopy and the intubation is performed with the Laryngobloc ®.~Group R (Reusable handle+ disposable metal blade): the first laryngoscopy is performed with the Laryngobloc ® and the second laryngoscopy and the intubation is performed with the R.
Study: NCT03719313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lonafarnib
Description: Lonafarnib (LNF) 50 mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lonafarnib
Description: Lonafarnib (LNF) 50 mg BID
Study: NCT04818476

Intervention type: PROCEDURE
Intervention: diagnostic endoscopic resection
Description: diagnostic endoscopic resection

Intervention type: PROCEDURE
Intervention: diagnostic endoscopic resection
Description: diagnostic endoscopic resection

Intervention type: PROCEDURE
Intervention: diagnostic endoscopic resection
Description: diagnostic endoscopic resection
Study: NCT01759459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: The medication will be administered immediately prior to receiving peripheral IV catheter placement

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buffered Lidocaine
Description: The medication will be administered immediately prior to receiving peripheral IV catheter placement

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacteriostatic Normal Saline
Description: The medication will be administered immediately prior to receiving peripheral IV catheter placement
Study: NCT00337935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin Alfa
Description: Epoetin alfa administered at 20,000 IU subcutaneously every 2 weeks for a period of 26 weeks
Study: NCT04543695

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XELOX
Description: Intravenous infusion of oxaliplatin (130 mg/m2 over 2 h) on day 1 and oral administration of capecitabine (1000 mg/m2 twice daily) from day 1 to day 14, is repeated every 3 weeks for 6 cycles.~6 courses，3 weeks per course

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOX
Description: Intravenous infusion of oxaliplatin (130 mg/m2 over 2 h) on day 1 and oral administration of capecitabine (1000 mg/m2 twice daily) from day 1 to day 14, is repeated every 3 weeks for 6 cycles.~6 courses，3 weeks per course

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOX
Description: Intravenous infusion of oxaliplatin (130 mg/m2 over 2 h) on day 1 and oral administration of capecitabine (1000 mg/m2 twice daily) from day 1 to day 14, is repeated every 3 weeks for 6 cycles.~6 courses，3 weeks per course

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFOX
Description: Administration of l-LV (400 mg/m2) and oxaliplatin (85 mg/ m2) by intravenous infusion over 2 h, followed by rapid intravenous infusion (iv) of 5-FU (400 mg/m2) and then slow infusion (civ) of 5-FU (2400 mg/m2 over 46 h), is repeated every 2 weeks for 9 cycles.
Study: NCT00337935

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Study: NCT00578331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olopatadine 0.6% nasal spray
Description: 2 sprays each nostril twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Nasal Spray
Description: 2 sprays each nostril twice daily
Study: NCT04543695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX
Description: Administration of l-LV (400 mg/m2) and oxaliplatin (85 mg/ m2) by intravenous infusion over 2 h, followed by rapid intravenous infusion (iv) of 5-FU (400 mg/m2) and then slow infusion (civ) of 5-FU (2400 mg/m2 over 46 h), is repeated every 2 weeks for 9 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX
Description: Administration of l-LV (400 mg/m2) and oxaliplatin (85 mg/ m2) by intravenous infusion over 2 h, followed by rapid intravenous infusion (iv) of 5-FU (400 mg/m2) and then slow infusion (civ) of 5-FU (2400 mg/m2 over 46 h), is repeated every 2 weeks for 9 cycles.
Study: NCT03737812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: elezanumab
Description: solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: elezanumab
Description: solution for infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: solution for infusion
Study: NCT02160496

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight loss interventional study with 20% protein-diet

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight loss interventional study with 27% protein-diet
Study: NCT04000412

Intervention type: DEVICE
Intervention: CardioZ multifrequency impedance recording system
Description: Patients will be submitted to mapping of both voltage and tissue impedance. The accuracy of the two maps identifying the extent and transmurality of the infarction will be assesssed by gadolinium imaging.
Study: NCT02160496

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight loss interventional study with 35% protein-diet
Study: NCT03757312

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Ocular ultrasound to measure optic nerve sheath diameter (ONSD).
Study: NCT01956201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20mg
Description: \[Atorvastatin Run-in Period\] Take Atorvastatin 20mg 1 tablet once a day (after breakfast) \[Treatment Period\] Take Atrovastatin 20mg/Fenofibrate 160mg or Atorvastiatin 20mg/Placebo of Finofibrate 160mg 2 tablet once a day (after breakfast) \[Extension Period\] Take Atrovastatin 20mg, Fenofibrate 160mg 2 tablet once a day (after breakfast)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 20mg
Description: \[Atorvastatin Run-in Period\] Take Atorvastatin 20mg 1 tablet once a day (after breakfast) \[Treatment Period\] Take Atrovastatin 20mg/Fenofibrate 160mg or Atorvastiatin 20mg/Placebo of Finofibrate 160mg 2 tablet once a day (after breakfast) \[Extension Period\] Take Atrovastatin 20mg, Fenofibrate 160mg 2 tablet once a day (after breakfast)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate 160mg
Description: Refer to Intervention Description of Atorvastatin 20mg
Study: NCT03176979

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contrast Agent
Description: Given IV
Study: NCT04543695

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TME
Description: Total mesorectal excision

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TME
Description: Total mesorectal excision

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TME
Description: Total mesorectal excision
Study: NCT03176979

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Digital Tomosynthesis Mammography
Description: Undergo CESM with DBT
Study: NCT02545764

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength and neuromuscular exercise programme
Description: 12 weeks strength and neuromuscular exercise programme for the lower extremity
Study: NCT03176979

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dual-Energy Contrast-Enhanced Digital Spectral Mammography
Description: Undergo CESM with DBT
Study: NCT01013805

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiotherapy
Description: Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day and continuous infusion 5-FU 200 mg/m2/day on the days of radiotherapy.~Weeks 8-10: as per Weeks 3-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Week 1: Oxaliplatin 100 mg/m2 Day 1 (over 2 hours), leucovorin 200mg/m2 Day 1 concurrent with oxaliplatin over 2 hrs (then 5-FU).~Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day Week 6: as per Week 1, Weeks 8-10: as per Weeks 3-5 Weeks 11: as per Week 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Week 1: (after Oxaliplatin and leucovorin)5-FU 400mg/m2 bolus Day 1, then 5-FU continuous infusion 2.4 g/m2 over 46 hours from Day 1.~Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day and continuous infusion 5-FU 200 mg/m2/day on the days of radiotherapy Week 6: as per Week 1, Weeks 8-10: as per Weeks 3-5 Weeks 11: as per Week 1.~Leucovorin 200 mg/m2 Day 1 concurrent with Oxaliplatin over 2 hrs, then 2nd: 5-FU 400 mg/m2 bolus Day 1, then 3rd: 5-FU continuous infusion 2.4 g/m2 over 46 hours from Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Week 1: Oxaliplatin 100 mg/m2 Day 1 (over 2 hours), leucovorin 200mg/m2 Day 1 concurrent with oxaliplatin over 2 hrs (then 5-FU) Week 6: as per Week 1, Weeks 11: as per Week 1.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Resection
Description: Surgery is to be performed according to the standard procedure for locally advanced rectal cancer 4 to 6 weeks after completion of the integrated preoperative radiotherapy with FOLFOX chemotherapy regimen.
Study: NCT00285857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovastatin
Description: Lovastatin 80 mg/day as 40 mg orally twice daily.~Lovastatin is approved by FDA as a cholesterol-lowering agent.
Study: NCT00974727

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Garden Fit
Description: 8-week summer gardening program. 9am-12pm on Monday, Wednesday, Friday and 9am-12:30pm on Tuesday and Thursday. Activities included gardening (preparing soil for planting, planting seeds and seedlings, mulching, weeding, watering, and harvesting), preparing meals with fresh foods from the garden, and other garden activities and games.
Study: NCT03260699

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCSI Rehabilitator brace
Description: Guardian Brace features the innovative Rehabilitator™ line of gait correcting, leg strengthening braces. Rehabilitator™ Knee Braces are clinically proven to reduce UNBRACED pain, strengthen the affected leg, and significantly improve function after only 90 days of brace wear.
Study: NCT03243318

Intervention type: DIAGNOSTIC_TEST
Intervention: MEPs induced by TMS
Description: Using TMS induced MEPs over motor cortex of the affected side to predict motor recovery potentials

Intervention type: DIAGNOSTIC_TEST
Intervention: MEPs induced by TMS
Description: Using TMS induced MEPs over motor cortex of the affected side to predict motor recovery potentials
Study: NCT02638168

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immediate Release Methylphenidate
Description: The medication assessment procedure will be a double-blind, within-subject evaluation of placebo and matching evening dose of IR MPH rounded to the nearest 2.5mg increment with a max IR MPH dose of 0.3mg/kg. Expected evening dose range will be from 2.5mg to 20mg with most participants receiving between 5 to 15mg per evening dose. Dose will be determined based on current dose of their morning extended release stimulant

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: inert placebo ingredient
Study: NCT00475904

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EpiCept-NP-1 Cream
Description: ketamine 4% amitriptyline 2% cream, twice daily for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin Capsules
Description: 1800mg/day capsules for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo cream and caps
Study: NCT02732782

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Eccentric exercise
Study: NCT00939562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxycycline monohydrate tablet
Description: Tablet, 100 mg, Single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxycycline carragenate tablet
Description: Tablet, 100 mg, Single dose
Study: NCT01288911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzalutamide
Description: capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bicalutamide
Description: tablets
Study: NCT03719313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir (RTV) 100 mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir (RTV) 100 mg BID
Study: NCT03746106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethoprim
Description: 300mg of trimethoprim will be given in combination with 5mg thiamine and compared to 5mg thiamine only for both Parts 1 and 2 of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 1000mg of metformin will be given in combination with 5mg thiamine and compared to 5mg thiamine only in Part 1 of the study.
Study: NCT01882699

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cereve Sleep System
Description: cerebral hypothermia
Study: NCT01240200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glargine
Description: oral antidiabetic agents plus once daily insulin glargine via an insulin syringe

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glargine
Description: oral antidiabetic agents plus once daily insulin glargine via an insulin syringe

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: glargine via insulin pen
Description: oral antidiabetic agents plus insulin glargine in a pre-filled pen

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: glargine via insulin pen
Description: oral antidiabetic agents plus insulin glargine in a pre-filled pen
Study: NCT03746106

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B1
Description: 5mg of thiamine will be given alone and in combination for both Parts 1 and 2 of the study.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin B1
Description: 5mg of thiamine will be given alone and in combination for both Parts 1 and 2 of the study.
Study: NCT01847989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: catridecacog
Description: Single doses of rFXIII administered intravenously (IV) to eight subjects in each of the five dose groups (2, 5, 10, 25 and 50 U/kg).
Study: NCT03746106

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B1
Description: 5mg of thiamine will be given alone and in combination for both Parts 1 and 2 of the study.
Study: NCT03776253

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial Care Conquer Fear Support intervention (psychoeducation, attention training, worry management, and detached mindfulness components)
Description: Attend CFS

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT00026312

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dinutuximab
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotretinoin
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: Given PO
Study: NCT01956201

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (Fenofibrate 160 mg)
Description: Refer to Intervention Description of Atorvastatin 20mg
Study: NCT02185339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: Intravenous infusion rate of rocuronium will be titrated to keep post-tetanic count between 1 to 2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: Intravenous infusion rate of rocuronium will be titrated to keep train-of-four count between 1 to 2.